Drugs / rAAV1-PG9DP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01937455 | Sep 2014 → Feb 2018 | HIV infectious disease | International AIDS Vaccine Initiative | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV1-PG9DP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01937455 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “rAAV1-PG9DP, a recombinant AAV1 vector encoding the gene for PG9” PMID 30885692 ↗ Mar 2019 |
| Route | Intramuscular | “rAAV1-PG9DP when administered intramuscularly” NCT01937455 ↗ |